These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18090059)

  • 41. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction.
    Keiser P; Nassar N; Skiest D; Andrews C; Yazdani B; White A; Hetherington S
    Int J STD AIDS; 2003 Jul; 14(7):478-81. PubMed ID: 12869229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vertigo and abacavir.
    Fantry LE; Staecker H
    AIDS Patient Care STDS; 2002 Jan; 16(1):5-7. PubMed ID: 11839213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abacavir gets green light from FDA advisory board. Food and Drug Administration.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glaxo opens broad expanded access program for abacavir (Ziagen).
    Baker R
    BETA; 1998 Apr; ():6. PubMed ID: 11365271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

  • 46. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 47. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Agranulocytosis and fever seven weeks after starting abacavir.
    Sankatsing SU; Prins JM
    AIDS; 2001 Dec; 15(18):2464-5. PubMed ID: 11774836
    [No Abstract]   [Full Text] [Related]  

  • 49. Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome.
    Llano A; Brander C
    Cell Res; 2012 Dec; 22(12):1637-9. PubMed ID: 22777424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 51. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
    Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC
    Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505
    [No Abstract]   [Full Text] [Related]  

  • 53. Monitoring abacavir bioactivation in humans: screening for an aldehyde metabolite.
    Grilo NM; Antunes AM; Caixas U; Marinho AT; Charneira C; Conceição Oliveira M; Monteiro EC; Matilde Marques M; Pereira SA
    Toxicol Lett; 2013 May; 219(1):59-64. PubMed ID: 23467017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system.
    Vilar FJ; Naisbitt DJ; Park BK; Pirmohamed M
    J HIV Ther; 2003 May; 8(2):42-7. PubMed ID: 12838164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abacavir and increased risk of myocardial infarction.
    Post FA; Campbell LJ
    Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
    [No Abstract]   [Full Text] [Related]  

  • 57. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

  • 58. Comment: Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Oct; 42(10):1519-20; author reply 1520-1. PubMed ID: 18780810
    [No Abstract]   [Full Text] [Related]  

  • 59. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The abacavir hypersensitivity reaction and interruptions in therapy.
    Loeliger AE; Steel H; McGuirk S; Powell WS; Hetherington SV
    AIDS; 2001 Jul; 15(10):1325-6. PubMed ID: 11426085
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.